GLP-1RAs combined with adipokine-targetingagents (e.g., leptin receptor agonists) may achieve more pronounced cardiacfunctional improvement through dual mechanisms involving central appetiteregulation and peripheral lipid metabolism in patients with obesity-relatedcardiomyopathy. The gene discussed is LEPR; the disease is Obesity.